New development of bio medicine in Baiji, Shenzhou, China

March 12, 2015 / BIOON / -- sigma Aldrich ® Corp (sigma Aldrich) today announced that its customized production service business unit SAFC ® commercial has signed a commercial sales and service contract with leading Chinese biopharmaceutical company Baiji Shenzhou The Beijing based innovative tumor drug treatment company reached an agreement with sigma Aldrich to select SAFC's mature and convenient chozn cell line production platform and personalized customized cell line engineering services, aiming to provide support for the discovery and commercial development of targeted tumor biological drugs in Baiji Shenzhou Kang Li, head of Baiji Shenzhou biopharmaceutical "The chozn platform has brought us great value in improving the expression of monoclonal antibodies and recombinant proteins and other targeted anti-tumor drugs Li Kang said that accelerating the product launch is crucial for every tumor drug project The main reason why we chose the chozn platform of SAFC is that it can shorten the research and development time of early biological drugs and As soon as possible to ensure the highest protein quality characteristics, in line with the production requirements of cell cloning Kevin guthall, global senior manager of the chozn platform in charge of SAFC, said: "after the first commercial deployment of GS - / - CHO cell line in the Asian market last year, SAFC recognized the keen demand and strong interest of Asia, a global emerging biomedical market, in highly expressing chozn cell platform Chozn provides an unparalleled and efficient solution for the development and production of biological drugs: shorten the development time of the project, ensure the key quality characteristics of protein, and improve the expression and quality of protein These are the hot spots and difficulties in the global biopharmaceutical industry "The chozn ® platform includes chozn ® GS - / - CHO cell lines and optimized cGMP compliant culture medium and supplement combinations (specifically for cell lines that maximize production of monoclonal antibodies and other proteins) The chozn ® cell line produced and tested by SAFC in accordance with cGMP is supported by sigma Aldrich's composr ® zinc finger nuclease (ZFN) technology It is the first commercially launched glutamine synthetase (GS) knockout Cho line on the market Baiji Shenzhou has established and improved the R & D platform for small molecule chemical drugs and large molecule biological drugs, which has attracted the attention of the industry since its establishment In 2013, Baiji Shenzhou signed a global cooperative development and sales agreement on two compound drugs with Merck xuelanuo In September 2014, Baiji Shenzhou announced that it received the milestone achievement income of 9 million US dollars from Merck xuelanuo bgb-290 project In December of the same year, Baiji Shenzhou completed financing of 450 million yuan, which will support the research and development of anti-cancer drugs It is expected that 2015 By the end of the year, five candidate drugs were put into clinical practice At present, there are three small molecule drugs for clinical development in Baiji Shenzhou Bgb-3111, a candidate drug for Btk inhibitors, entered the first phase of clinical practice in August 2014 The PARP inhibitor bgb-290 entered clinical phase I in July 2014 The second generation of B-Raf inhibitor bgb-283 entered clinical phase I in November 2013 In September 2014, Baiji Shenzhou and Boehringer Ingelheim announced to sign a strategic cooperation agreement, which will enable Boehringer Ingelheim to provide biopharmaceutical production for clinical trials of new immune tumor drugs independently developed by Baiji Shenzhou About Baiji Shenzhou (Beijing) Biotechnology Co., Ltd is a Chinese biotechnology and new drug creation company located in Zhongguancun Life Science Park, Beijing It is committed to research and develop innovative anti-cancer drugs including new chemical small molecules and biological large molecules Through independent development of new drugs found in its Chinese laboratories and cooperation with pharmaceutical partners, Baiji has authorized the joint development of new drugs under development to meet the medical needs of cancer patients in China and Asia Baiji is creating a solid biomarker and bioinformatics platform to identify the subsets of cancer patients most likely to benefit from related drugs or treatment methods, and to develop more effective and safer targeted innovative drugs by studying the relationship between drug sensitivity and target molecules About SAFC SAFC commercial is the custom production and service business unit of sigma Aldrich Corporation The Department is one of the top 10 suppliers of fine chemicals and biological agents recognized worldwide As a reliable manufacturer for life science and high-tech industries, SAFC uses global centers of excellence and specialized production facilities to work closely with customers to meet development challenges and accelerate production of product lines The division's rich product and service portfolio includes high-purity inorganic materials for high-tech applications, raw material cell culture media / additives for biopharmaceutical production, a wide range of biopharmaceutical safety testing services, and complex high activity APIs and key intermediates for pharmaceutical production China's BeiGene Selects SAFC CHOZN ®   Platform for Commercial Drug Development ST LOUIS， March 11， 2015 /PRNewswire/ -- Sigma-Aldrich ®   Corporation (NASDAQ： SIAL) today announced that SAFC ®   Commercial ( www.sigma-aldrich.com/safc )， its custom manufacturing services business unit， has entered a commercial sales and service contract with leading biopharmaceutical company， BeiGene ( www.beigene.com ) Located in Beijing， the innovative oncology company purchased SAFC's off-the-shelf， turnkey CHOZN cell line production platform and cell line engineering services to support discovery and commercial development of BeiGene's targeted oncology drug "The CHOZN Platform offers us a great deal of value through the ability to maximize the production of monoclonal antibodies and other recombinant-proteins used in our targeted oncology treatments，" said Dr Kang Li， Head of Biologics from BeiGene "Reducing timelines are critical to every oncology development project Our objective in selecting SAFC's CHOZN Platform and services was to shorten bioproduction times in early development and to obtain a manufacturing clone quickly with the highest protein quality specifications." "Following last year's first commercial placement of the GS-/- CHO cell line in the Asian markets， SAFC is seeing significant interest in using our CHOZN recombinant cell line development platforms in the region，" said Kevin Gutshall， Global Senior Manager of the CHOZN Platform for SAFC "The CHOZN Platform supports efficient innovation and the highest quality therapeutics It offers a turnkey solution that is unmatched in the industry Users simply identify and clone the genes for their therapeutic protein of interest into the CHOZN expression vector， and then employ the traditional cell line development strategies of transfection， selection and cloning The CHOZN Platform is designed to deliver a robust producing clone - ready for manufacturing." Enabled by Sigma-Aldrich's， CompoZr ®   Zinc Finger Nuclease (ZFN) gene editing technology， the first commercially available glutamine synthetase (GS) knockout CHO line was brought to market in 2011 The full CHOZN Platform includes the CHOZN GS-/- CHO cell line and an optimized set of cGMP-produced and chemically defined media and feeds.  In addition to the cell line， media， and feed， SAFC provides extensive user support， which includes working with customers on protocols - from transfection through to scale-up in bioreactors， as well as comprehensive cell-line safety testing and development history For more information about the CHOZN Platform， visit： http：//www.sigmaaldrich.com/safc-choznplatform About SAFC： SAFC Commercial， the custom manufacturing and services business unit of Sigma-Aldrich Corporation， is recognized as a top 10 global specialty chemicals and biologics supplier As a trusted manufacturer for the life science and high-technology industries， SAFC works closely with customers to resolve development challenges and accelerate the product pipeline using its global "Centers of Excellence" and dedicated manufacturing facilities Its rich portfolio includes high-purity inorganic materials for high-tech applications， critical raw materials and extensive biologics safety-testing services for biopharmaceutical manufacturing， and complex， high-potent APIs and key intermediates for pharmaceutical manufacturing For more information， visit www.sigma-aldrich.com/safc About Sigma-Aldrich： Sigma-Aldrich， a leading Life Science and Technology company focused on enhancing human health and safety， manufactures and distributes 250，000 chemicals， biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets With three distinct business units - Research， Applied and SAFC Commercial - Sigma-Aldrich is committed to enabling science to improve the quality of life The Company operates in 37 countries， has approximately 9，300 employees worldwide and had sales of $2.79 billion in 2014 For more information about Sigma-Aldrich， please visit its website at www.sigma-aldrich.com 2015 Sigma-Aldrich Co LLC All rights reserved Sigma-Aldrich and SAFC are trademarks of Sigma-Aldrich Co LLC or its affiliates， registered in the U.S and other countries